Endocrine Abstracts

Introduction: GLP-1 agonists and metformin are widely used antidiabetic drugs with excellent blood glucose-lowering effects, but patients very often develop side effects. The most common side effect of these two groups of drugs is gastrointestinal intolerance in the form of vomiting, diarrhoea, general weakness and dizziness.Case ReportA 58-year-old male patient was hospitalised for the second time in one month due to a recurrence of dizziness, vomiting, ataxia and epileptic s...

A 57-year-old female patient was presented to the neurologist in the ER because of her first grand mal-type seizure. Initial examination in the emergency department confirmed hyponatremia (Na 131 mmol/l) in laboratory findings, while CT scan of the brain and EEG were normal. During hospitalization, additional laboratory and imaging studies were performed. Neuroradiological examination was performed (CT scan of the brain, MRI of the brain and MRI of the pituitary gland), which ...

Female patient (56 y) with hyperthyroidism (start TSH 0.01 mIU/l; fT3 15.8 pmol/l; fT4 39.4 pmol/l) one month after initiation of thiamazole therapy (10 mg 3 × 1/1 week, then 2 × 1) came to the emergency room with symptoms of sweating, palpitations, nervousness, itching, fever (37.6 C), icterus. In medical history: oesophageal achalasia surgery 5 years ago, non-smoker. Therapy: thiamazole, bisoprolol, alprazolam. Initially in laboratory findi...

Distinguishing type 1 from type 2 diabetes mellitus (DM) depends on clinical presentation, titers of antibodies and requirement for insulin therapy. Need for insulin per se is not a major difference between those two types. We measured the presence of antibodies for glutamic acid decarboxylase (GAD), islet–cell antibodies (ICA), insulinoma–associated protein 2 (IA–2) and the level of C–peptide in a group of 10 patients whose diagnosis of type 2 DM was e...

Introduction: In patients with non-controlled type 2 diabetes mellitus (DM2) and obesity treated with oral therapy, liraglutide treatment should improve glycemic and metabolic control.Materials and methods: Retrospective descriptive study. Liraglutide treatment was started in 46 outpatients with uncontrolled DM2. The effect of therapy was evaluated between September 2013 and January 2016. Age, sex, duration of diabetes, weight, BMI, HbA1c, fasti...